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The results of a high-throughput screening assay using the dengue virus-2 replicon showed that the
imidazole 4,5-dicarboxamide (I45DC) derivative (15a) has a high dengue virus inhibitory activity.
Based on 15a as a lead compound, a novel class of both disubstituted I45DCs and the resembling
pyrazine 2,3-dicarboxamides (P23DCs) were synthesized. Here, we report on their in vitro inhibitory
activity against dengue virus (DENV) and yellow fever virus (YFV). Some of these ﬁrst generation
compounds have shown activity against both viruses in the micromolar range. Within this series,
compound 15b was observed to display the highest antiviral potency against YFV with an
EC50 ¼ 1.85 mM. In addition, compounds 20a and 20b both potently inhibited replication of DENV
(EC50 ¼ 0.93 mM) in Vero cells.
© 2014 The Authors. Published by Elsevier Masson SAS. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/3.0/).1. Introduction
Dengue is the most common arthropod-borne viral infection in
the world and is estimated to transmit 390 million new infections
every year [3]. Dengue virus (DENV) belongs to the Flavivirus genus
of the Flaviviridae. The genome of DENV is comprised of a 10.7 kb,
single, positive-stranded RNAwith at least four different circulating
serotypes (DENV-1 to DENV-4) [4]. Reportedly, a ﬁfth serotype now
complicates vaccine development [4]. With increased levels of
population growth, urbanization, and international travel, DENV
illness has increased 30-fold in the last 50 years [5]. Most of the
current research on dengue infections is focused on the treatment
of symptoms, which often can be a tedious and intensive process.
As there is neither a drug nor any vaccine available to combat DENV
infections till date [6], it is highly important to explore and uncover
small molecules that have potent anti-dengue activity. In the past
half-decade, a number of antiviral agents with such inhibitory
properties have been discovered. These include an adenosine
analog 1 [7], a N-sulfonylanthranilic acid derivate 2 [8], the
chlorophenyl-thiophene derivate 3 [9], and most recently some
2,4-diaminoquinazoline derivatives 4 [10] (see Fig. 1).1,2].
n.be (A. Van Aerschot).
r Masson SAS. This is an open acceUnfortunately, none of these substances have entered into clinical
trials. Hence, further development of new chemical entities
endowed with dengue inhibitory properties is warranted. Our
previous efforts herein, focused on tritylated and alkylated nucle-
oside analogs, resulting in compounds endowed with strong anti-
ﬂavivirus inhibitory properties. However, no clear SAR could be
determined [1,2]. Hence we now turned our attention to another
lead molecule.
The ﬁve-membered imidazole ring is a structural unit found in
many biologically active compounds. The strong therapeutic
properties of imidazole containing drugs have encouraged medic-
inal chemists to synthesize a large number of novel chemothera-
peutic agents comprising this entity. Amongst others, imidazole
core structures are found in different carboxypeptidase, hemeox-
ygenase and lactamase inhibitors, as well as among anti-
inﬂammatory, anticancer, antibacterial, antifungal, antitubercular,
antidiabetic and antiviral products, further highlighted with some
examples. Ramya et al. synthesized a series of novel 5-(nitro/
bromo)-styryl-2-benzimidazole derivatives (5) and tested them for
their antibacterial activity against Staphylococcus aureus, Escher-
ichia coli and likewise evaluated the antifungal activity against
Candida albicans and Aspergillus fumigates [11]. Biological activities
proved comparable to ciproﬂoxacin. Kavitha C.S. et al. synthesized a
series of 2-methylaminobenzimidazole derivatives in which com-
pound 6 showed analgesic and anti-inﬂammatory activity compa-
rable with the standard drug nimesulide [12]. Cenzo et al.ss article under the CC BY license (http://creativecommons.org/licenses/by/3.0/).
Fig. 1. Structures of some recently described antiviral compounds being inhibitory for dengue virus.
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and their 2-thione analogs and found antitumor activity [13].
Finally, Sharma et al. synthesized imidazole derivatives for antiviral
screening and different [2-(substituted phenyl)-imidazol-1-yl]-
benzamides like 8 and 9 were selected as the most promising
antiviral agents [14] (see Fig. 2).
Imidazole-4,5-dicarboxylic acid (I45DC) and its derivatives such
as those bearing primary or secondary amides have previously
been reported to be active against HIV-1 protease [15]. Likewise,
some derivatives of this scaffold were uncovered as potential kinase
inhibitors with antiproliferative activity against HL-60 cells [16]. In
addition, inhibition of proteineprotein interaction between Hepa-
titis C glycoprotein E2 and CD81 has been reported previously [17].
The I45DCs are known as well to be a structural component of some
antibiotics [18] and also to affect memory [19]. Substitution on the
imidazole moiety herein has been reported, both in solution phase
as well as in a combinatorial fashion on solid support.
High throughput screening of a compound library led to the
identiﬁcation of N5-(4-ﬂuorophenyl)-N4-(4-methyl-2-(3-methyl-
1H-pyrazol-5-yl)phenyl)-1H-imidazole-4,5-dicarboxamide 15a
(see Fig. 3) with an EC50 of 2.50 mM and 3.47 mM against DENV and
YFV, respectively. In search for new compounds with potential for
clinical use as antiviral agents, a series of compounds based on this
I45DC scaffold were synthesized with regiospeciﬁc attachment of
the substituents and these analogs were investigated for their
inhibitory properties against DENV and YFV. In addition, the
imidazole core was substituted for a pyrazine ring leading to a se-
ries of pyrazine-2,3-dicarboxylic acids (P23DC). The intended sub-
stitution of the central imidazole ring would result in slightly
different orientation of the attached amide groups, and in a change
of the hydrogen bonding pattern exchanging the combination of a
hydrogen donating and a hydrogen accepting nitrogen into two
hydrogen accepting nitrogen atoms. In this communication, we
report on the synthesis and biological activity of both new series of
dissymmetric I45DCs and P23DCs, which we studied for their
inhibitory properties against YFV and DENV.
2. Results and discussion
2.1. Synthetic aspects
The general procedure employed for the synthesis of dissym-
metrically disubstituted I45DCs is shown in Scheme 1. Imidazole-4,5-dicarboxylic acid 10was allowed to reﬂuxwith SOCl2 in toluene
with catalytic DMF to afford pyrazinedione diacid dichloride 11 in
92% yield [20]. The literature route for amide formation suggests
hydrolysis of the acid chlorides to carboxylic acids by the addition
of water. Amines are then added to open both acyl imidazole bonds
affording two identical imidazole analogs. Baures et al., replaced
the water with phenol, thereby modulating the reactivity of the
acid chloride in comparison with an acyl imidazole bond for the
subsequent addition of two different amines [20]. The difﬁculty in
preparing such analogs is that their synthesis is highly dependent
upon the substituents to be introduced. Primary benzyl amines, for
example, are too reactive to provide selectivity in the reaction,
whereas anilines can be added in a proper stoichiometric ratio in
order to provide a pyrazine dione intermediate 12 which can often
be puriﬁed by crystallization. In the case of aniline derivatives, the
resulting pyrazine intermediates are often insoluble in the reaction
solvent and can be isolated simply by vacuum ﬁltration. In parallel,
different bromoanilines or benzylamines were subsequently
coupled with commercially available heterocyclic boronic acids
through palladium catalyzed Suzuki reaction to give the desired
second aniline in 60e75% yield. Addition of this second aniline to
the pyrazine intermediates 12aec resulted in opening of the acyl
imidazole bond to obtain the expected product. Based on this
approach, a series of novel molecules was prepared within this
I45DC family containing various substituted phenyl rings. For some
of the ﬁnal products 15, the reaction sequence was changed with
prior attachment of the aniline carrying a heterocycle.
Pyrazines are important pharmacophores present in a number
of biologically active compounds such as antimycobacterial, anti-
bacterial, antidiabetic, and hypnotic agents. To further explore
previous structureeactivity relationship, we planned to substitute
the ﬁve-membered imidazole ring with a pyrazine ring. Hereto,
regioselective functionalization of the pyrazine started from com-
mercial pyrazine-2,3-dicarboxylic acid (P23DA) and a four-step
synthesis of the target compounds has been described in Scheme
2. P23DA was converted to its corresponding anhydride 17 by
treatment with acetic anhydride at room temperature.
Reaction with p-ﬂuoroaniline or p-toluidine resulted in opening
of the ﬁve-membered ring with concomitant formation of the ﬁrst
amide bond (18a,b). Reaction with triﬂuoroacetic anhydride at 0 C
afforded the anhydric activated product 19a or 19b allowing
introduction of the second amide. Hereto, the intermediate was
reacted with preformed anilines or benzyl amines 14aem to give
Fig. 2. Some examples of imidazole containing structures endowed with pronounced biological activity.
Fig. 3. Lead compound 15a and envisaged modiﬁcations of different parts of the antiviral lead for optimization of the structure.
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products were puriﬁed by silica gel chromatography and charac-
terized by 1H NMR, 13C NMR and HRMS before evaluation of their
inhibitory properties against DENV and YFV.2.2. Assessment of antiviral activity
As shown in Fig. 3 and Schemes 1 and 2, four main structural
domains were chosen for optimization of hit 15a: the aromatic
moiety (ring A), the central pyrazine/imidazole core (ring B), the
substituted aromatic moiety (ring C) and the heterocyclic group
(ring D). These efforts have provided a few compounds that
exhibited an improved biological proﬁle with respect to the initial
lead compound 15a. Overall, improvement or reduction of the
inhibitory activities for either DENV or YFV is mostly running in
parallel.
The overall structure of 15a comprises an imidazole core car-
rying two aniline moieties coupled via an amide bond, with one of
the aniline rings substituted with an additional heterocyclic ring
(ring D). Therefore, our efforts to understand the structureeactivity
relationship of the initial lead started with modifying theheterocyclic moiety as shown in Table 1. Using p-ﬂuoroaniline (ring
A) and the I45DC core as a ﬁxed fragment, substitution of the ﬁve-
membered pyrazole moiety (ring D) with a thienyl or furanyl ring
mostly led to considerable loss of activity (i.e., compare 15h,15i,15j
versus 15a). However, activity remarkably was restored upon sub-
stitution of a methyl group for the para-ﬂuorine in ring A (15k,15l).
The benzylamine substitution for ring A likewise annihilated the
inhibitory properties (15m), while in contrast a p-ﬂuoro-phenyl-
ethylamine again displayed nice activity (15n). Exchanging aniline
ring C for a benzylamine preserved the activity when the supple-
mentary heterocycle D was attached at the ortho position (15c,
15d), while para substitution led to considerable loss of activity
(15eeg) within this context. A single attempt with an amino-
pyridine ring at site C proved inactive (15o). Overall, the com-
pounds 15b (EC50 ¼ 1.85 mM, YFV),15c (EC50 ¼ 1.93 mM, DENV),15d
(EC50 ¼ 2.61 mM, YFV) and 15k (EC50 ¼ 2.02 mM, DENV) are
endowed with the best inhibitory properties within this imidazole
series.
With these results in mind, we hoped to further improve the
potency via replacement of the central ﬁve-membered imidazole
(ring B) with a pyrazine scaffold, both rings containing two nitrogen
Scheme 1. General reaction scheme for synthesis of the I45DC analogs. Conditions: a) SOCl2, cat. DMF, Toluene, 85 C; b) DIPEA, substituted aniline, DCM, 10 C; c) acetoni-
trile:water (1:1), K2CO3, PdCl2TPP2, boronic acid; d) DIPEA, substituted aniline or benzyl amine, DCM, room temperature (rt).
Scheme 2. General scheme for assembly of different P23DC analogs. Conditions: a) acetic anhydride; b) acetonitrile:water (1:1), substituted aniline, dodecyl hydrogen sulfate
sodium salt, rt; c) triﬂuoroacetic anhydride, TEA, THF; d) substituted aniline or benzyl amine, THF, rt.
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substituents. Focusing on compound 15c as most potent repre-
sentative for inhibition of DENV (EC50 ¼ 1.92 mM), we synthesized a
series of pyrazine analogs with a pyridine substituent as the het-
erocyclic moiety D, attached at different positions of ring C. The
inhibitory potency of these compounds was likewise examined
against DENV and YFV and is summarized in Table 2 (compounds
20a20n).
Unfortunately, the compound 20f corresponding to 15c,
exhibited 20-fold decrease in activity against DENV
(EC50 ¼ 40.70 mM) and 6-fold against YFV (EC50 ¼ 21.29 mM).
Concentrating on anti-DENV activity, we noticed within the imid-
azole series that the para attachment of the heterocycle to ring Cproved deleterious for the biological activity (see 15eeg). In
contrast with these results, the para-pyrimidin-4-yl substituent on
ring C proved advantageous within the pyrazine series and led to
compound 20a displaying a 2-fold increase in anti-DENV potency
with EC50 of 0.93 mM. A distinction however can be made having
either a benzylamine (n ¼ 1) or an aniline (n ¼ 0) aromatic ring C.
Within the benzylamine series, the heterocycle is preferred at the
para position with preference for concomitant presence of ﬂuo-
roaniline at the A-site (20a, 20c) over toluidine (20h, 20j). However,
ortho attachment of the heterocycle on the benzylamine ring
seriously reduced the activity (20f, 20m). Having an aniline ring at
site C the results were less clear with mostly intermediate inhibi-
tory properties (5e25 mM), except for the strongly inhibiting
Table 1
Inhibitory properties for yellow fever virus and dengue virus of the imidazole analogs 15ae15o.
Sr. No. n1 n2 R1 R2 Heterocycle (positiona) Dengue Yellow fever
EC50 (mM) CC50 (mM) SI EC50 (mM) CC50 (mM) SI
15a 0 0 F p-Methyl 3-Methyl-1H-pyrazol-5-yl (ortho)
Initial Lead
2.50 >120 48 3.47 >120 34.5
15b 0 0 F H 3-Methyl-1H-pyrazol-5-yl (ortho) 6.03 21.7 3.6 1.85 >121 67
15c 0 1 F H Pyridin-4-yl (ortho) 1.93 50.1 26 3.90 >120 31
15d 0 1 F H Thien-3-yl (ortho) 8.88 17.32 1.95 2.61 34.5 13.2
15e 0 1 F H Pyridin-3-yl (para) 42.10 >120 2.85 11.81 >118 10
15f 0 1 F H Thien-3-yl (para) 33.69 20.21 0.60 28.77 >119 4.13
15g 0 1 F H Pyridin-4-yl (para) >120 >120 1 >120 >120 1
15h 0 0 F p-Methyl Thien-3-yl (ortho) 48.75 >117 2.4 >119 >119 1
15i 0 0 F p-Methyl Furan-2-yl (ortho) >123.6 >124 1 ND e e
15j 0 0 H p-Methyl Thien-3-yl (ortho) >124 >124 1 9.20 >120 13
15k 0 0 CH3 p-Methyl Thien-3-yl (ortho) 2.02 >50 24.5 >120 >120 1
15l 0 0 CH3 p-Methyl Furan-2-yl (ortho) 3.47 >125 36.2 ND e e
15m 1 0 H p-Methyl Furan-2-yl (ortho) >125 >125 1 ND e e
15n 2 0 F p-Methyl Furan-2-yl (ortho) 3.77 >116.5 30.9 ND e e
15o 0 0 H p-Methyl See structure above >120 26.40 0.22 >120 >119 0.97
a Indicates the attachment point of the heterocycle on the phenyl ring.
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series (20aen) the YFV inhibitory properties in general were
slightly weaker compared to DENV inhibition by these compounds.
3. Conclusion
A series of tetracyclic inhibitors were prepared using I45CD and
P23DC scaffolds and which further were part of a structur-
eactivity investigation. The SAR results of both series, I45DCs and
P23DCs derivatives, as potent anti-dengue and anti-yellow fever
virus agents are described above. Our investigation led to the dis-
covery of 15b, which is the most potent inhibitor of the series
(EC50¼ 1.85 mM) against YFV, but followed closely in potency by the
quite deviating structure 15d. The structural analog 15c on the
other hand proved most inhibitory for dengue virus (see Fig. 4). In
addition, within the pyrazine series both compounds 20a and 20b
were found to have potent DENV inhibitory properties
(EC50¼ 0.93 mM) uncovered to date. Key features of these inhibitors
include the central bis-amide arrangement which is found to be a
metal-chelating component in many drugs. In summary, determi-
nation of the antiviral activities shows that I45DC and P23DC are
attractive candidate scaffolds for further studies and the interesting
activities observed so far, warrant an in depth study of their
mechanism of action.
4. Materials and methods
All other chemicals were provided by Aldrich or ACROS and
were of the highest quality. 1H and 13C NMR spectra were deter-
mined with a 300 MHz Varian Gemini apparatus with tetrame-
thylsilane as internal standard for the 1H NMR spectra (s ¼ singlet,
d¼ doublet, dd¼ double doublet, t¼ triplet, br. s¼ broad signal, br.
d ¼ broad doublet, m ¼multiplet) and the solvent signal e DMSO-
d6 (d ¼ 39.6 ppm) or CDCl3 (d ¼ 76.9 ppm) e for the 13C NMRspectra. Exact mass measurements were performed with a quad-
rupole/orthogonal acceleration time-of-ﬂight tandem mass spec-
trometer (qTOF2, Micromass, Manchester, UK) ﬁtted with a
standard electrospray ionization (ESI) interface. All solvents were
carefully dried or bought as such.
4.1. Chemistry
4.1.1. 5,10-Dioxo-5,10-dihydrodiimidazo[1,5-a:10,50-d]pyrazine-1,6-
dicarbonyl dichloride (11)
To a dry round-bottom ﬂask was added 1.0 g of imidazole-4,5-
dicarboxylic acid (10, 1 mmol) and 10 mL of toluene. To this stir-
red suspension were added 3.0 mL of thionyl chloride (6.5 mmol)
and 0.250mL of DMF (catalytic). The resultingmixturewas reﬂuxed
for 16 h. After the mixture was cooled in ice bath, the solid product
was collected by vacuum ﬁltration, washed with two 20 mL por-
tions of toluene, and dried under vacuum to yield 0.95 g of crude 11
(Yield: 95%) as a yellow solid. This product was used further
without characterization.
4.1.2. General procedure for 12aee
To a suspension of 11 (1.0 mmol) in 10 mL of dichloromethane
was added N,N-diethylaniline (2 mmol), and corresponding
substituted aniline (1.7 mmol) at 10 C. The reaction mixture was
stirred at room temperature for 3e5 h before collecting highly
insoluble colored solid 12aee by vacuum ﬁltration. The product
was washed with portions of 10 mL DCM, cold water, and acetone,
respectively.Note: Addition of excess of aniline results in opening of
acyl imidazole bonds affording unwanted products.
4.1.2.1. 5,10-Dioxo-N1,N6-diphenyl-5,10-dihydrodiimidazo[1,5-a:10,50-
d]pyrazine-1,6-dicarboxamide (12a). Yield: 85%; Orange solid; 1H
NMR (300 MHz, CDCl3): d 10.74 (s, 2H), 9.09 (s, 2H), 7.80 (d, 4H,
J ¼ 7.8 Hz), 7.41 (t, 4H, J ¼ 8.1 Hz), 7.17 (t, 2H, J ¼ 7.5 Hz). 13C NMR
Table 2
Inhibitory properties for yellow fever virus and dengue virus of the pyrazine containing compounds 20ae20n.
Sr. No. n R1 R2 Heterocycle (positiona) Dengue Yellow fever
EC50 (mM) CC50 (mM) SI EC50 (mM) CC50 (mM) SI
20a 1 F H Pyridin-4-yl (para) 0.94 >117.5 >125 7.49 >120 16
20b 0 F p-Methyl Pyridin-3-yl (ortho) 0.94 >117.5 >125 13.10 >118 9
20c 1 F H Pyridin-3-yl (para) 2.99 >115.1 38.5 8.90 >116 13
20d 0 F H Pyridin-4-yl (ortho) 11.71 >117.1 10.4 8.22 >123.3 15
20e 0 F H Pyridin-3-yl (ortho) 23.19 >120.5 5.2 47.53 >119 2.5
20f 1 F H Pyridin-4-yl (ortho) 40.70 >118.0 2.9 21.29 >127 6
20g 0 F p-Methyl Pyridin-4-yl (ortho) >117 >117 1 48.43 >125 2.6
20h 1 CH3 H Pyridin-4-yl (para) 16.60 74.7 4.5 36.83 >110.5 3
20i 0 CH3 p-Methyl Pyridin-3-yl (ortho) 10.55 47.5 4.5 18.41 75.5 4.1
20j 1 CH3 H Pyridin-3-yl (para) 6.75 >116.1 17.2 73.08 >124 1.7
20k 0 CH3 H Pyridin-4-yl (ortho) 4.71 >122.5 26 12.46 >125 10
20l 0 CH3 H Pyridin-3-yl (ortho) 14.56 >128.13 8.8 >122 >122 1
20m 1 CH3 H Pyridin-4-yl (ortho) 57.86 >118 2.04 70.61 >120 1.7
20n 0 CH3 p-Methyl Pyridin-4-yl (ortho) 11.90 >119 10 30.93 >117.5 3.8
a Indicates the attachment point of the heterocycle on the phenyl ring.
Fig. 4. Overview of all new compounds most inhibitory to either DENV or YFV as reported in this communication.
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124.5, 120.1. HRMS calcd for C22H15N6O4 [MþH]þ: 427.1149; found:
427.1151.
4.1.2.2. N1,N6-bis(4-ﬂuorophenyl)-5,10-dioxo-5,10-dihydrodiimidazo
[1,5-a:10,50-d]pyrazine-1,6-dicarboxamide (12b). Yield: 87%; Yellow
Solid; 1H NMR (300 MHz, CDCl3): d 10.76 (s, 2H), 9.09 (s, 2H),
7.85e7.81 (m, 4H), 7.25 (m, 4H, J ¼ 9.0 Hz). 13C NMR (75 MHz,
CDCl3): d 160.3, 158.1, 157.2, 149.0, 145.0, 138.6, 134.8, 134.8, 122.1,
122.0, 120.7, 115.5. HRMS calcd for C22H15N6O4 [MþH]þ: 427.1149;found: 427.1151. HRMS calcd for C22H13F2N6O4 [MþH]þ: 463.0961;
found: 463.0961.4.1.2.3. 5,10-Dioxo-N1,N6-di-p-tolyl-5,10-dihydrodiimidazo[1,5-
a:10,50-d]pyrazine-1,6-dicarboxamide (12c). Yield: 89%; Red Solid;
1H NMR (600 MHz, DMSO): d 10.62 (s, 2H), 9.07 (s, 2H), 7.67 (d, 4H,
J ¼ 8.4 Hz), 7.20 (d, 4H, J ¼ 7.8 Hz), 2.30 (s, 6H). 13C NMR (125 MHz,
DMSO): d157.8, 149.2, 145.2, 138.6, 135.9, 133.5, 129.4, 120.4, 120.0,
20.6. HRMS calcd for C22H15N6O4 [MþH]þ: 427.1149; found:
M. Saudi et al. / European Journal of Medicinal Chemistry 87 (2014) 529e539 535427.1151. HRMS calcd for C24H19N6O4 [MþH]þ: 455.1462; found:
455.1461.
4.1.2.4. N1,N6-bis(4-methyl-2-(thiophen-2-yl)phenyl)-5,10-dioxo-
5,10-dihydrodiimidazo [1,5-a:10,50-d]pyrazine-1,6-dicarboxamide
(12d). Yield: 74%; Red Solid; 1H NMR (300 MHz, DMSO): 10.01 (s,
2H), 8.97 (s, 2H), 7.79e7.63 (m, 6H), 7.35e7.23 (m, 6H), 2.37 (s, 6H,
2CH3). HRMS calcd for C32H23N6O4S2 [MþH]þ: 619.1237; found:
619.1238. In view of insufﬁcient solubility 13C NMR could not be
determined.
4.1.2.5. N1,N6-bis(2-(furan-2-yl)-4-methylphenyl)-5,10-dioxo-5,10-
dihydrodiimidazo[1,5-a:10,50-d]pyrazine-1,6-dicarboxamide (12e).
Yield: 72%; Yellow Solid; 1H NMR (300 MHz, DMSO): 10.46 (s, 2H),
9.07 (s, 2H), 7.81e7.61 (m, 6H), 7.25e6.63 (m, 6H), 2.38 (s, 6H,
2CH3). HRMS calcd for C32H23N6O6 [MþH]þ: 587.1673; found:
587.1672. In view of insufﬁcient solubility 13C NMR could not be
determined.
4.1.3. General procedure for 14aem
To a solution of corresponding aniline/benzyl amine (1.0 mmol)
in 10 mL dioxane:water (1:1), was added anhydrous K2CO3
(1.5 mmol), aryl boronic acids (1.2 mmol) and Pd(TPP)2Cl2
(0.025mmol) in a seal tube. The mixture was purgedwith argon for
30 min at rt and heated at 100 C for 1 h in microwave. All reactions
and manipulations were run under argon atmosphere. After
completion, the solvent was evaporated under reduced pressure
and the residue was puriﬁed by column chromatography on a silica
gel to give the desired product.
4.1.3.1. 2-(5-Methyl-1H-pyrazol-3-yl)aniline (14a) [21]. Yield: 52%;
White solid; 1H NMR (300 MHz, CDCl3): d 7.50 (d, 1H, J ¼ 7.2 Hz),
7.13 (t, 1H, J ¼ 7.5 Hz), 6.79e6.75 (m, 2H), 6.39 (s, 1H), 2.37 (s, 3H,
CH3).
4.1.3.2. 4-Methyl-2-(pyridin-3-yl) aniline (14b). Yield: 62%; Yellow
Oil; 1H NMR (300 MHz, CDCl3): d 8.70 (s, 1H), 8.61e8.59 (m, 1H),
7.83e7.80 (m, 1H),7.40e7.35 (m, 1H), 7.05e7.01 (m, 1H), 6.94 (m,
1H), 6.73e6.71 (d, 1H, J ¼ 8.1 Hz), 3.60 (bs, 2H, NH2), 2.30 (s, 3H,
CH3). 13C NMR (75 MHz, CDCl3): d 149.2, 147.4, 140.3, 135.7, 130.0,
129.0, 127.3, 122.6, 115.2, 19.5. HRMS calcd for C12H13N2 [MþH]þ:
185.1073; found: 185.1078.
4.1.3.3. 4-Methyl-2-(pyridin-4-yl)aniline (14c). Yield: 59%; White
solid; 1H NMR (300 MHz, CDCl3): d 8.69e8.67 (m, 2H), 7.44e7.42
(m, 2H), 7.06e6.96 (m, 2H), 6.72 (d, 1H, J ¼ 8.1 Hz), 3.69 (bs, 2H,
NH), 2.30 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3): d 150.4, 130.6,
130.5, 124.0, 116.4, 20.5. HRMS calcd for C12H13N2 [MþH]þ:
185.1073; found: 185.1074.
4.1.3.4. 2-(Pyridin-3-yl)aniline (14d). Yield: 72%; Yellow solid; 1H
NMR (300 MHz, CDCl3): d 8.73 (s, 1H), 8.62e8.60 (m,1H), 7.84e7.80
(m, 1H), 7.41e7.36 (m, 1H), 7.24e7.11 (m, 2H), 6.89e6.79 (m, 2H),
3.75 (bs, 2H, NH2). 13C NMR (75 MHz, CDCl3): d 150.2, 148.6, 143.9,
136.6, 135.4, 130.7, 129.5, 123.6, 119.0, 116.0. HRMS calcd for
C11H11N2 [MþH]þ: 171.0917; found: 171.0921.
4.1.3.5. 2-(Pyridin-4-yl)aniline (14e). Yield: 69%; White solid; 1H
NMR (300 MHz, CDCl3): d 8.69e8.67 (m, 2H), 7.44e7.28 (m, 2H),
7.25e7.13 (m, 2H), 6.89e6.78 (m, 2H), 3.82 (bs, 2H, NH2). 13C NMR
(75 MHz, CDCl3): d 149.4, 129.2, 128.8, 123.0, 118.0, 115.2. HRMS
calcd for C11H11N2 [MþH]þ: 171.0917; found: 171.0925.
4.1.3.6. (4-(Pyridin-3-yl)phenyl)methanamine (14f). Yield: 55%;
White solid; 1H NMR (300 MHz, CDCl3): d 8.86 (m, 2H), 8.61e8.59(m, 1H), 7.91e7.87 (m, 1H), 7.60e7.57 (m, 2H), 7.47e7.40 (m, 2H),
7.38e7.36 (m, 1H), 3.96 (s, 2H, CH2), 1.62 (bs, 2H, NH2). 13C NMR
(75 MHz, CDCl3): d 149.9, 127.5, 126.8, 121.1, 45.7. HRMS calcd for
C12H13N2 [MþH]þ: 185.1073; found: 185.1072.
4.1.3.7. (4-(Pyridin-4-yl)phenyl)methanamine (14g) [22]. Yield:
59%; White solid; 1H NMR (300 MHz, CDCl3): d 8.64e8.62 (m, 2H),
7.61e7.41 (m, 6H), 3.92 (s, 2H, CH2), 1.77 (bs, 2H, NH2). 13C NMR
(75 MHz, CDCl3): d 149.2, 126.9, 126.2, 120.5, 45.1.
4.1.3.8. (2-(Pyridin-4-yl)phenyl)methanamine (14h) [23]. Yield:
65%; White solid; 1H NMR (300 MHz, CDCl3): d 8.76e8.74 (m, 1H),
7.56e7.10 (m, 8H), 3.92 (s, 2H, CH2). 13C NMR (75 MHz, CDCl3):
d 149.1,132.0,131.3,131.1,131.1,128.2,127.7,127.6,127.5,126.9,122.7,
120.5, 46.0.
4.1.3.9. 4-Methyl-2-(thiophen-3-yl)aniline (14i). Yield: 62%; Off-
white solid; 1H NMR (300 MHz, CDCl3): d 7.47e7.40 (m, 2H),
7.33e7.31 (m, 1H), 7.09 (s, 1H), 7.03e7.00 (m, 1H), 6.75e6.72 (d, 1H,
J ¼ 8.1 Hz), 3.73 (bs, 2H, NH2), 2.33 (s, 3H, CH3). 13C NMR (75 MHz,
CDCl3): d 141.5, 140.1, 130.7, 129.1, 128.5, 127.8, 126.0, 122.6, 122.5,
116.0, 20.5. HRMS calcd for C11H12N1S1 [MþH]þ: 190.0685; found:
190.0686.
4.1.3.10. (4-(Thiophen-3-yl)phenyl)methanamine (14j) [24].
Yield: 58%; Off-white solid; 1H NMR (300 MHz, CDCl3): d 7.61e7.58
(m, 2H), 7.47e7.28 (m, 6H), 3.92 (s, 2H, CH2). 13C NMR (75 MHz,
CDCl3): d 127.7, 126.8, 126.5, 126.3, 120.2, 46.3.
4.1.3.11. 2-(Thiophen-3-yl)phenyl)methanamine (14k) [25].
Yield: 52%; White solid; 1H NMR (300 MHz, CDCl3): d 7.58e7.12 (m,
6H), 3.91 (s, 2H, CH2). 13C NMR (150 MHz, CDCl3): d 162.1, 160.8,
160.5, 142.0, 141.1, 135.8, 132.7, 130.1, 129.8, 129.3, 129.0, 128.8,
128.6,128.4,128.2,127.7,127.5,127.4,127.1,127.0,126.8,125.5,125.0,
123.4, 122.7, 46.8, 44.2.
4.1.3.12. 2-(Furan-2-yl)-4-methylaniline (14l). Yield: 63%; White
solid; 1H NMR (300 MHz, CDCl3): d 7.52 (s, 1H), 7.32 (s, 1H),
6.97e6.94 (m, 1H), 6.71e6.52 (m, 3H), 2.30 (s, 3H, CH3). 13C NMR
(75 MHz, CDCl3): d 152.5, 141.2, 140.8, 129.5, 127.8, 127.6, 116.9,
116.2, 111.3, 106.3, 20.4. HRMS calcd for C11H12N1O1 [MþH]þ:
174.0913; found: 174.0910.
4.1.3.13. 5-Methyl-3-(5-methylthiophen-2-yl)pyridin-2-amine
(14m). Yield: 57%; White solid; 1H NMR (300 MHz, CDCl3): d 7.84
(s, 1H), 7.28 (s, 1H), 6.99 (d, J ¼ 3.3 Hz, 1H), 6.73e6.72 (m, 1H), 4.96
(bs, 2H, NH2), 2.49 (s, 3H, CH3), 2.18 (s, 3H, CH3). 13C NMR (75 MHz,
CDCl3): d 153.6, 146.5, 139.8, 138.5, 137.1, 125.6, 125.5, 122.7, 114.5,
17.0, 14.9.
4.1.4. General procedure for 15beo
To a stirred solution of 12aee (1.0 mmol) in 10 mL DCM, was
added DIPEA (3.0 mmol), and 14aem (3.0 mmol) under argon at-
mosphere at room temperature. The mixture was allowed to reﬂux
for 16e48 h. Two alternative workup procedures were followed
depending on whether the product precipitated out of solution or
not.
Workup 1 (for soluble products): The DCM was evaporated using
a rotavapor. The product was puriﬁed by ﬂash chromatography on
silica gel.
Workup 2 (for insoluble products): The precipitate was collected
by ﬁltration using a Buchner funnel and washed on the frit with
DCM (20e25 mL) until the yellow impurities had disappeared. The
product obtained from this workup procedure did not need chro-
matographic puriﬁcation.
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phenyl)-1H-imidazole-4,5-dicarboxamide (15b). Yield: 86%; 1H
NMR (500 MHz, DMSO): d 13.69 (bs, 1H, NH), 13.30 (bs, 1H, NH),
13.05 (bs, 1H, NH), 12.78 (bs, 1H, NH), 8.65 (d,1H, J¼ 8.0 Hz), 7.96 (s,
1H), 7.78e7.23 (m, 9H), 6.54 (s, 1H), 2.31 (s, 3H, CH3). 13C NMR
(125 MHz, DMSO): d 163.3, 159.6, 158.0, 156.4, 150.3, 140.2, 137.3,
135.2, 135.0, 133.9, 130.0, 128.7, 124.8, 123.2, 121.9, 121.6, 116.4,
116.2, 103.1, 10.8. HRMS calcd for C21H16F1N6O2 [MH]þ: 403.1324;
found: 403.1323.
4.1.4.2. N5-(4-ﬂuorophenyl)-N4-(2-(pyridin-4-yl)benzyl)-1H-imid-
azole-4,5-dicarboxami-de (15c). Yield: 83%; 1H NMR (600 MHz,
DMSO): d 8.76 (d, 0.5H, J ¼ 6.6 Hz), 7.96e7.17 (m, 10H), 4.57 (d, 2H,
J ¼ 6.0 Hz, CH2). 13C NMR (150 MHz, DMSO): d 159.5, 157.9, 150.0,
137.4, 127.1, 134.8, 132.7, 132.4, 131.8, 131.7, 129.3, 129.1, 129.0, 128.7,
128.1, 122.4, 122.0, 116.0, 115.8, 43.1. HRMS calcd for C23H18F1N5O2
[MH]þ: 414.1372; found: 414.1372.
4.1.4.3. N5-(4-ﬂuorophenyl)-N4-(2-(thiophen-3-yl)benzyl)-1H-imid-
azole-4,5-dicarbox amide (15d). Yield: 86%; 1H NMR (600 MHz,
DMSO): d 13.53 (bs, 0.5H, NH), 13.45 (bs, 0.5H, NH), 9.40 (bs, 0.5H,
NH), 9.23 (bs, 0.5H, NH), 7.99e7.18 (m, 12H), 4.58 (d, 2H, J ¼ 6.6 Hz,
CH2). 13C NMR (150 MHz, DMSO): d 164.3, 156.1, 140.5, 137.3, 137.0,
132.7, 132.5, 129.9, 129.0, 128.0, 127.6, 127.1, 126.3, 123.7, 121.1, 115.9,
115.7, 42.9. HRMS calcd for C22H16F1N4O2S1 [MH]þ: 419.0973;
found: 419.0967.
4.1.4.4. N5-(4-ﬂuorophenyl)-N4-(4-(pyridin-3-yl)benzyl)-1H-imid-
azole-4,5-dicarboxamide (15e). Yield: 76%; 1H NMR (600 MHz,
DMSO): d 13.55 (s, 1H, NH), 13.49 (bs, 1H, NH), 10.49 (s, 1H), 10.06 (s,
1H), 9.47 (s, 1H), 8.85e7.20 (m, 9H), 4.59 (d, 2H, J¼ 6.6 Hz, CH2). 13C
NMR (150 MHz, DMSO): d 164.2, 156.4, 148.6, 147.7, 139.3, 137.2,
136.0, 135.6, 135.1, 134.4, 133.0, 128.9, 128.4, 128.3, 127.3, 127.2,
124.2, 121.4, 121.4, 116.1, 116.9, 42.3. HRMS calcd for C23H17F1N5O2
[MH]þ: 414.1372; found: 414.1372.
4.1.4.5. N5-(4-ﬂuorophenyl)-N4-(4-(thiophen-3-yl)benzyl)-1H-imid-
azole-4,5-dicarboxamide (15f). Yield: 78%; 1H NMR (300 MHz,
DMSO): d 9.84 (bs, 1H, NH), 7.97 (s, 1H), 7.87e7.19 (m, 15H), 4.57 (d,
2H, J ¼ 6.3 Hz, CH2). 13C NMR (75 MHz, DMSO): d 160.1, 157.0, 141.4,
141.4, 138.0,137.0, 134.9,134.0, 128.1, 128.0, 127.6, 127.1, 126.3, 126.0,
121.7, 121.6, 120.9, 120.7, 115.9, 115.6, 42.2. HRMS calcd for
C22H16F1N5O2 S1 [MH]þ: 419.0983; found: 419.0993.
4.1.4.6. N5-(4-ﬂuorophenyl)-N4-(4-(pyridin-4-yl)benzyl)-1H-imid-
azole-4,5-dicarboxamide (15g). Yield: 81%; 1H NMR (600 MHz,
DMSO) d 13.56 (s, 1H, NH), 13.47 (bs, 1H, NH), 9.50 (s, 1H, NH),
8.61e7.20 (m,13H), 4.59 (d, 2H, J¼ 6.0 Hz, CH2). 13C NMR (150MHz,
DMSO): d 164.2, 156.2, 150.5, 150.3, 146.9, 140.4, 137.1, 135.9, 135.0,
133.0, 128.8, 128.3, 128.2, 127.1, 127.0, 121.3, 121.2, 116.0, 115.9, 42.2.
HRMS calcd for C23H17F1N5O2 [MH]þ: 414.1372; found: 414.1369.
4.1.4.7. N5-(4-ﬂuorophenyl)-N4-(4-methyl-2-(thiophen-3-yl)
phenyl)-1H-imidazole-4,5-dicarboxamide (15h). Yield: 89%; 1H
NMR (500 MHz, DMSO): d 13.64 (s, 0.7H, NH), 13.56 (s, 0.3H, NH),
13.22 (s, 0.7H, NH), 12.44 (s, 0.3H, NH), 10.46 (s, 0.3H, NH), 10.12 (s,
0.7H, NH), 7.99e7.15 (m, 13H), 2.36 (s, 3H, CH3). 13C NMR (125 MHz,
DMSO): d 162.5, 156.0, 138.3, 137.1, 136.7, 135.2, 134.9, 132.9, 131.5,
130.7, 130.6, 130.0, 129.2, 128.6, 128.6, 128.4, 128.4, 127.0, 126.2,
124.9, 124.2, 124.0, 122.9, 199.9, 121.2, 121.2, 116.0, 115.8, 115.2, 115.1,
20.6. HRMS calcd for C22H18F1N5O2 S1 [MH]þ: 421.1128; found:
421.1117.
4.1.4.8. N5-(4-ﬂuorophenyl)-N4-(2-(furan-2-yl)-4-methylphenyl)-
1H-imidazole-4,5-dicarboxamide (15i). Yield: 77%; 1H NMR(300 MHz, DMSO): d 13.69 (bs, 1H, NH), 13.20 (bs, 1H, NH), 10.60 (s,
1H, NH), 8.05e7.55 (m, 6H), 7.27e6.56 (m, 5H), 2.38 (s, 3H, CH3).
HRMS calcd for C22H18F1N4O3 [MþH]þ: 405.1357; found: 405.1353.4.1.4.9. N4-(4-methyl-2-(thiophen-3-yl)phenyl)-N5-phenyl-1H-imid-
azole-4,5-dicarboxamide (15j). Yield: 81%; 1H NMR (600 MHz,
DMSO): d 13.63 (s, 0.7H, NH), 13.56 (s, 0.3H, NH), 13.18 (s, 0.7H, NH),
12.47 (s, 0.3H, NH), 10.34 (s, 0.3H, NH), 10.12 (s, 0.7H, NH), 7.96e7.12
(m, 12H), 2.36 (s, 3H, CH3). 13C NMR (125 MHz, DMSO): d 162.4,
156.0, 138.5, 138.3, 137.1, 135.2, 132.8, 131.5, 130.6, 129.9, 129.3,
128.6, 128.4, 127.0, 124.2, 124.0, 120.9, 119.4, 20.6. HRMS calcd for
C22H17N4O2 S1 [MH]þ: 401.1078; found: 401.1078.4.1.4.10. N4-(4-methyl-2-(thiophen-3-yl)phenyl)-N5-(p-tolyl)-1H-
imidazole-4,5-dicarboxamide (15k). Yield: 79%; 1H NMR (600 MHz,
DMSO): d 13.59 (s, 0.7H, NH),13.54 (s, 0.3H, NH), 13.09 (s, 0.3H, NH),
12.52 (s, 0.7H, NH), 10.26 (s, 0.3H, NH), 10.10 (s, 0.7H, NH), 7.98e7.18
(m, 10H), 2.36 (s, 3H, CH3), 2.28 (s, 3H, CH3). 13C NMR (125 MHz,
DMSO): d 162.4, 155.8, 138.3, 137.0, 136.0, 135.1, 133.1, 132.7, 131.5,
130.6, 129.9, 129.6, 129.4, 129.0, 128.6, 128.5, 128.4, 128.4, 127.0,
124.2, 124.0, 120.9, 119.4, 20.6. HRMS calcd for C23H21N4O2S1
[MþH]þ: 417.1380; found: 417.1377.4.1.4.11. N4-(2-(furan-2-yl)-4-methylphenyl)-N5-(p-tolyl)-1H-imid-
azole-4,5-dicarboxamide (15l). Yield: 76%; 13.58 (s, 0.7H, NH), 13.52
(s, 0.3H, NH), 13.07 (s, 0.3H, NH), 12.50 (s, 0.7H, NH), 10.23 (s, 0.3H,
NH), 10.08 (s, 0.7H, NH), 7.97e7.93 (m, 2H), 7.71e7.56 (m, 4H),
7.33e7.11 (m, 5H), 2.35 (s, 3H, CH3), 2.28 (s, 3H, CH3). 13C NMR
(125 MHz, DMSO): d 162.4, 155.8, 138.3, 136.9, 136.0, 135.1, 133.1,
132.7, 131.5, 130.6, 129.8, 129.6, 129.4, 129.0, 128.6, 128.5, 128.4,
128.4, 127.0, 124.2, 124.0, 120.9, 119.4, 20.6, 20.6. HRMS calcd for
C23H21N4O3 [MþH]þ: 401.1608; found: 401.1602.4.1.4.12. N5-benzyl-N4-(2-(furan-2-yl)-4-methylphenyl)-1H-imid-
azole-4,5-dicarboxamide (15m). Yield: 83%; 1H NMR (300 MHz,
CDCl3): d 11.84 (bs, 1H, NH), 11.57 (bs, 1H, NH), 10.32 (bs, 1H, NH),
8.16 (d, 1H, J ¼ 8.4 Hz), 7.61e7.18 (m, 10H), 6.74 (d, 1H, J ¼ 3.3 Hz),
6.57e6.55 (m,1H), 4.70 (d, 2H, J¼ 6.0 Hz, CH2), 2.40 (s, 3H, CH3). 13C
NMR (75MHz, CDCl3): d 161.7, 159.0,142.4,134.9,134.8,130.5,129.1,
128.6, 127.9, 127.4, 127.2, 123.0, 111.7, 108.5, 43.5, 21.0. HRMS calcd
for C23H21N4O3 [MþH]þ: 401.1608; found: 401.1590.4 .1.4 .13 . N5- (4-ﬂuorophenethyl ) -N4- (2- ( furan-2-yl ) -4-
methylphenyl)-1H-imidazole-4,5-dicarboxamide (15n). Yield: 75%;
1H NMR (300 MHz, CDCl3): d 11.13 (bs, 1H, NH), 10.32 (bs, 1H, NH),
8.18 (d, 1H, J ¼ 8.7 Hz), 7.67e6.55 (m, 10H), 3.73 (m, 2H, CH2), 3.00
(t, 2H, J¼ 7.5 Hz CH2), 2.42 (s, 3H, CH3). 13C NMR (150 MHz, DMSO):
d 161.5, 157.9, 157.1, 150.6, 150.3, 143.1, 142.8, 142.3, 142.2, 138.4,
137.4, 136.8, 136.5, 135.7, 135.0, 133.3, 132.6, 130.4, 130.2, 129.0,
128.7, 128.3, 127.6, 127.3, 127.1, 125.5, 125.0, 124.5, 123.8, 118.0, 115.7,
115.4,113.1,112.8,112.1,109.1,108.9, 77.1, 60.9, 34.81. HRMS calcd for
C24H22FN4O3 [MþH]þ: 433.1670; found: 433.1668.4.1.4.14. N5-(5-methyl-3-(5-methylthiophen-2-yl)pyridin-2-yl)-N4-
phenyl-1H-imidazole-4,5-dicarboxamide (15o). Yield: 76%; 1H NMR
(600 MHz, CDCl3): d 13.63 (bs, 1H, NH), 13.08 (bs, 0.7H, NH), 12.92
(bs, 0.3H, NH), 10.70 (bs, 0.7H, NH), 10.54 (bs, 0.3H, NH), 8.31e7.08
(m, 8H), 6.79e6.76 (m, 1H), 2.39 (s, 3H, CH3), 2.36 (s, 3H, CH3). 13C
NMR (150 MHz, CDCl3): d 184.6, 149.5, 147.4, 144.6, 143.7, 141.2,
138.3,138.2,137.4,137.3,135.6,132.9,129.3,129.2,129.1,128.5,127.1,
126.8, 126.3, 128.5, 17.5, 15.1. HRMS calcd for C22H19N5O2S1
[MH]þ: 416.1187; found: 416.1187.
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Sodium dodecyl sulfate (SDS, 6 mmol) was added to a stirred
heterogeneous suspension of amine (5 mmol) in water (20 mL)
until a homogeneous solution was formed, (in case of turbidity, the
mixture was warmed to obtain a clear solution). Anhydride 17
(5 mmol) dissolved in acetonitrile (5 mL) was added to this solution
in one lot. After stirring for 1 h at room temperature, the acetoni-
trile was evaporated and the product precipitated from the aqueous
layer. To the aqueous solution containing precipitate, solid sodium
hydrogen carbonate was added pinch-wise until the effervescence
ceased and the pHwas 6.0. The remaining precipitated product was
ﬁltered, washed with water (20 mL), dried in a vacuum desiccator.
In cases where the product did not precipitate, the reactionmixture
was extracted with ethyl acetate (2  25 mL). The combined
organic extracts were dried with anhydrous Na2SO4 and the solvent
was removed in a rotary evaporator under reduced pressure to
yield the pure product.
4.1.5.1. 3-((4-Fluorophenyl)carbamoyl)pyrazine-2-carboxylic acid
(18a) [26]. Yield: 72%; White solid; 1H NMR (300 MHz, DMSO):
d 10.86 (bs, 1H), 8.90 (s, 2H), 7.83e7.78 (m, 2H), 7.22 (t, 2H,
J ¼ 9.0 Hz).
4.1.5.2. 3-(p-Tolylcarbamoyl)pyrazine-2-carboxylic acid (18b) [27].
Yield: 65%; White solid; 1H NMR (300 MHz, DMSO): d 10.68 (bs,
1H), 8.88 (s, 2H), 7.67 (d, J ¼ 8.4 Hz, 2H), 7.17 (t, J ¼ 8.4 Hz, 2H), 2.29
(s, 3H, CH3). 13C NMR (75 MHz, DMSO): d 166.5, 162.3, 146.5, 145.8,
145.6, 144.6, 136.0, 133.4, 129.3, 120.2, 20.7.
4.1.6. General procedure for 19aeb
Triﬂuoroacetic anhydride (1.5 equiv) was added dropwise to a
stirring solution of acid 18aeb (1 equiv) and Et3N (TEA, 3 equiv) in
1,4-dioxane (20 mL) that was kept at 0 C with an ice bath. After
15 min the yellow solution was allowed to warm to room tem-
perature and was stirred for 30 min, then it was poured in cold H2O
(100 mL). A precipitate formed, which was collected by ﬁltration
using a Buchner funnel and washed with H2O. The product was
dried overnight under high vacuum.
4.1.6.1. (Z)-7-((4-ﬂuorophenyl)imino)furo[3,4-b]pyrazin-5(7H)-one
(19a). Yield: 70%; Off-white solid; 1H NMR (300 MHz, CDCl3):
d 9.06 (d, 2H, J ¼ 5.1 Hz), 7.73e7.69 (m, 2H), 7.15 (t, J ¼ 8.4 Hz, 2H).
13C NMR (75 MHz, CDCl3): d 150.9, 149.5, 128.7, 128.6, 116.2, 116.0.
4.1.6.2. (Z)-7-(p-tolylimino)furo[3,4-b]pyrazin-5(7H)-one (19b).
Yield: 66%;White solid; 1H NMR (300MHz, CDCl3): d 9.07e9.03 (m,
2H), 7.69e7.28 (m, 4H), 2.43 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3):
d 150.5, 149.0, 129.5, 126.4, 21.0.
4.1.7. General procedure for 20aen
Phthalisoimide 19aeb (1 equiv) was added to stirring solution of
the aniline/benzylamine 14aem (1.2 equiv) in THF. The mixture
was stirred overnight at room temperature. The THF was evapo-
rated on a rotavapor. Themixturewas dilutedwith EtOAc (triple the
volume of THF) and washed three times with 1 M HCl. The organic
phase was dried with Na2SO4 and evaporated. The product was
puriﬁed by ﬂash chromatography on silica gel.
4.1.7.1. N2-(4-ﬂuorophenyl)-N3-(4-(pyridin-4-yl) benzyl) pyrazine-
2,3-dicarboxamide (20a). Yield: 76%; 1H NMR (300 MHz, DMSO):
d 10.65 (bs, 1H, NH), 9.45 (t, J ¼ 6.6 Hz, 1H, NH), 8.88 (q, 2H,
J¼ 2.4 Hz), 8.64e8.61 (m, 2H), 7.78e7.69 (m, 6H), 7.50 (d, J¼ 8.4 Hz,
2H), 7.21 (t, J ¼ 9.0 Hz, 2H), 2.39 (d, J ¼ 6.3 Hz, 2H, CH2). 13C NMR
(75 MHz, DMSO): d 164.0, 163.7, 160.1, 156.9, 150.3, 148.3, 146.9,
145.4, 145.3, 144.5, 140.5, 135.8, 135.5, 128.3, 126.9, 121.7, 121.6,121.2, 115.7, 115.4, 42.2. HRMS calcd for C24H19F1N5O2 [MþH]þ:
428.1517; found: 428.1520.
4.1.7.2. N2-(4-ﬂuorophenyl)-N3-(4-methyl-2-(pyridin-3-yl) phenyl)
pyrazine-2,3-dicarboxamide (20b). Yield: 74%; 1H NMR (300 MHz,
CDCl3): d 9.02 (bs, 1H, NH), 8.69e8.54 (m, 5H), 8.27 (d, J ¼ 8.4 Hz,
1H), 7.84 (d, J ¼ 8.1 Hz, 1H), 7.70e7.66 (m, 2H), 7.36e7.26 (m, 2H),
7.11e7.03 (m, 3H), 2.39 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3):
d 161.8, 161.5, 150.1, 149.1, 144.3, 137.3, 135.7, 134.2, 131.8, 131.0,
130.1, 123.7, 123.2, 122.2, 122.1, 116.1, 115.8, 21.1. HRMS calcd for
C24H19F1N5O2 [MþH]þ: 428.1517; found: 428.1514.
4.1.7.3. N2-(4-ﬂuorophenyl)-N3-(4-(pyridin-3-yl) benzyl) pyrazine-
2,3-dicarboxamide (20c). Yield: 72%; 1H NMR (300 MHz, CDCl3):
d 9.33 (bs, 1H, NH), 8.76 (bs, 1H, NH), 8.63 (s, 2H), 8.54e8.52 (d,
J ¼ 4.8 Hz, 1H), 7.86e7.27 (m, 9H), 7.05 (m, J ¼ 8.7 Hz, 2H), 4.76 (d,
J ¼ 6.0 Hz, 2H, CH2). 13C NMR (75 MHz, CDCl3): d164.9, 161.6, 161.5,
148.6, 148.3, 147.6, 146.1, 144.6, 144.0, 137.8, 137.3, 136.3, 134.4,
133.6, 128.8, 127.6, 123.7, 122.1, 122.0, 116.0, 115.7, 43.7. HRMS calcd
for C24H19F1N5O2 [MþH]þ: 428.1517; found: 428.1517.
4.1.7.4. N2-(4-ﬂuorophenyl)-N3-(2-(pyridin-4-yl) phenyl) pyrazine-
2,3-dicarboxamide (20d). Yield: 66%; 1H NMR (300 MHz, CDCl3):
d 10.72 (bs, 1H, NH), 10.27 (bs, 1H, NH), 8.90e8.86 (m, 2H),
8.58e8.56 (m, 2H), 7.85e7.76 (m, 3H), 7.55e7.37 (m, 5H), 7.22 (t,
J¼ 9.0 Hz, 2H). 13C NMR (75MHz, CDCl3): d 163.2,163.1, 149.8,147.0,
146.2, 145.1, 144.9, 135.2, 134.4, 133.6, 130.3, 129.3, 126.6, 126.2,
124.0, 121.9, 121.8, 115.7, 115.4, 79.3. HRMS calcd for C23H17F1N5O2
[MþH]þ: 414.1361; found: 414.1363.
4.1.7.5. N2-(4-ﬂuorophenyl)-N3-(2-(pyridin-3-yl) phenyl) pyrazine-
2,3-dicarboxamide (20e). Yield: 76%; 1H NMR (300 MHz, CDCl3):
d 9.04 (bs, 1H, NH), 8.78 (bs, 1H, NH), 8.70e8.56 (m, 4H), 8.45 (d,
J ¼ 8.1 Hz, 1H), 7.87 (d, J ¼ 7.8 Hz, 1H), 7.72e7.69 (m, 2H),
7.52e7.7.28 (m, 4H), 7.07 (t, J ¼ 8.7 Hz, 2H). 13C NMR (75 MHz,
CDCl3): d 161.7, 161.5, 150.1, 149.2, 144.3, 137.3, 134.4, 134.0, 133.5,
130.5, 129.9, 129.5, 125.8, 123.7, 123.1, 122.2, 122.1, 116.1, 115.8.
HRMS calcd for C23H17F1N5O2 [MþH]þ: 414.1361; found: 414.1365.
4.1.7.6. N2-(4-ﬂuorophenyl)-N3-(2-(pyridin-4-yl) benzyl) pyrazine-
2,3-dicarboxamide (20f). Yield: 68%; 1H NMR (600 MHz, DMSO):
d 10.67 (bs, 1H, NH), 9.41 (t, J ¼ 6.0 Hz, 1H), 8.91e8.89 (m, 2H),
7.75e7.19 (m, 8H), 4.51 (d, J ¼ 6.0 Hz, 2H). 13C NMR (125 MHz,
DMSO): d 164.3, 163.6, 159.2, 157.6, 150.6, 149.0, 148.1, 145.3, 144.5,
137.4, 135.3, 132.4, 129.0, 128.5, 127.8, 122.1, 121.5, 115.5, 115.4, 42.9.
HRMS calcd for C24H19F1N5O2 [MþH]þ: 428.1517; found: 428.1520.
4.1.7.7. N2-(4-ﬂuorophenyl)-N3-(4-methyl-2-(pyridin-4-yl)phenyl)
pyrazine-2,3-dicarbox amide (20g). Yield: 76%; 1H NMR (300 MHz,
CDCl3): d 8.95 (bs, 1H, NH), 8.66e8.58 (m, 5H), 8.32 (d, J ¼ 8.4 Hz,
1H), 7.72e7.67 (m, 2H), 7.43 (d, J ¼ 8.4 Hz, 2H), 7.30 (d, J ¼ 8.4 Hz,
2H), 7.13e7.7.04 (m, 3H), 2.40 (s, 3H, CH3). 13C NMR (75 MHz,
CDCl3): d 150.0, 145.9, 144.0, 143.8, 130.9, 130.0, 129.9, 124.0, 122.6,
121.7, 121.6, 115.6, 115.3, 20.6. HRMS calcd for C24H19F1N5O2
[MþH]þ: 428.1517; found: 428.1518.
4.1.7.8. N2-(4-(pyridin-4-yl) benzyl)-N3-(p-tolyl) pyrazine-2,3-
dicarboxamide (20h). Yield: 78%; 1H NMR (300 MHz, CDCl3):
d 9.19 (bs, 1H, NH), 8.66e8.62 (m, 4H), 7.64e7.47 (m, 8H), 7.17 (d,
J ¼ 8.1 Hz, 3H), 4.78 (d, J ¼ 6.0 Hz, 2H, CH2), 2.36 (s, 3H, CH3). 13C
NMR (75MHz, CDCl3): d 165.1, 161.2, 150.4, 148.1, 148.0, 145.8, 144.8,
143.8, 139.0, 137.6, 134.9, 134.8, 129.7, 128.8, 127.5, 121.7, 120.3, 43.7,
21.1. HRMS calcd for C25H22N5O2 [MþH]þ: 424.1768; found:
424.1765.
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2,3-dicarboxamide (20i). Yield: 76%; 1H NMR (300 MHz, CDCl3):
d 8.95 (bs, 1H, NH), 8.72e8.56 (m, 5H), 8.33 (d, J ¼ 8.1 Hz, 1H), 7.89
(d, J ¼ 7.5 Hz, 1H), 7.62 (d, J ¼ 8.1 Hz, 2H), 7.38e7.14 (m, 4H), 2.42 (s,
3H, CH3), 2.37 (s, 3H, CH3). 13C NMR (75MHz, CDCl3): d 150.2, 149.2,
144.5,144.1, 137.3, 135.5, 134.8,134.2,131.9, 131.0, 130.1,123.6,123.3,
120.3, 21.1. HRMS calcd for C25H22N5O2 [MþH]þ: 424.1768; found:
424.1767.
4.1.7.10. N2-(4-(pyridin-3-yl) benzyl)-N3-(p-tolyl) pyrazine-2,3-
dicarboxamide (20j). Yield: 71%; 1H NMR (300 MHz, CDCl3):
d 9.24 (bs, 1H, NH), 8.78e8.54 (m, 4H), 7.88e7.84 (m, 1H), 7.63 (d,
J ¼ 8.4 Hz, 2H), 7.56e7.17 (m, 8H), 4.79 (d, J ¼ 6.0 Hz, 2H, CH2), 2.36
(s, 3H, CH3). 13C NMR (75 MHz, CDCl3): d 165.2, 161.2, 148.6, 148.3,
148.1, 145.7, 144.6,143.8,137.9,137.2, 136.4,134.9,134.7,134.4,129.7,
128.9, 127.6, 123.7, 120.3, 43.7, 21.1. HRMS calcd for C25H22N5O2
[MþH]þ: 424.1768; found: 424.1769.
4.1.7.11. N2-(2-(pyridin-4-yl) phenyl)-N3-(p-tolyl) pyrazine-2,3-
dicarboxamide (20k). Yield: 72%; 1H NMR (300 MHz, CDCl3):
d 8.95 (bs, 1H, NH), 8.68e8.51 (m, 6H), 7.63 (d, J ¼ 8.4 Hz, 2H),
7.50e7.19 (m, 7H), 2.37 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3):
d 150.5, 146.2, 144.6, 144.1, 134.9, 134.1, 129.9, 129.8, 125.7, 124.5,
123.0, 120.3, 21.1. HRMS calcd for C24H20N5O2 [MþH]þ: 410.1611;
found: 410.1608.
4.1.7.12. N2-(2-(pyridin-3-yl) phenyl)-N3-(p-tolyl) pyrazine-2,3-
dicarboxamide (20l). Yield: 68%; 1H NMR (300 MHz, CDCl3):
d 8.70 (bs, 1H, NH), 8.70e8.47 (m, 6H), 7.90 (d, J ¼ 7.8 Hz, 2H),
7.63e7.18 (m, 8H), 2.36 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3):
d 162.0, 160.1, 149.6, 148.5, 144.0, 143.7, 137.0, 123.2, 134.0, 133.6,
120.0, 129.2, 129.1, 125.2, 123.2, 122.8, 119.8, 20.6. HRMS calcd for
C24H20N5O2 [MþH]þ: 410.1611; found: 410.1606.
4.1.7.13. N2-(4-(pyridin-4-yl) benzyl)-N3-(p-tolyl) pyrazine-2,3-
dicarboxamide (20m). 1H NMR (300 MHz, CDCl3): d 9.13 (bs, 1H,
NH), 8.77e8.66 (m, 3H), 7.71e7.16 (m, 11H), 4.82 (s, 2H, CH2), 2.36
(s, 3H, CH3). 13C NMR (75 MHz, CDCl3): d 161.3, 150.8, 144.6, 143.9,
136.9,132.9,130.5,129.7,129.4,128.7,128.6,128.0,121.6,120.3, 44.3,
21.1. HRMS calcd for C25H22N5O2 [MþH]þ: 424.1768; found:
424.1768.
4.1.7.14. N2-(4-methyl-2-(pyridin-4-yl) phenyl)-N3-(p-tolyl) pyr-
azine-2,3-dicarboxamide (20n). Yield: 73%; 1H NMR (300 MHz,
CDCl3): d 8.94 (bs, 1H, NH), 8.68e8.62 (m, 4H), 8.49 (bs, 1H, NH),
8.37 (d, J ¼ 8.4 Hz, 1H), 7.63 (d, J ¼ 8.4 Hz, 2H), 7.48e7.14 (m, 6H),
2.42 (s, 3H, CH3), 2.37 (s, 3H, CH3). 13C NMR (75 MHz, CDCl3):
d 161.3, 150.5, 146.4, 144.5, 144.1, 134.8, 131.5, 130.4, 129.8, 124.5,
123.2, 120.3, 21.1. HRMS calcd for C25H22N5O2 [MþH]þ: 424.1768;
found: 424.1770.
4.2. Antiviral activity determination for DENV and YFV
Green monkey kidney cells [Vero-B cells as obtained from the
European Collection of Cell Cultures (ECACC)] were grown in
minimum essential medium (MEM; Gibco, Merelbeke, Belgium)
supplemented with 10% fetal calf serum (FCS), 1% L-glutamine and
1% sodium bicarbonate. Vero-B cells were seeded at a density
7  103 cells/well in 100 mL assay medium and allowed to adhere
overnight. Antiviral assays were performed in medium supple-
mented with 2% FCS, 1% L-glutamine and 1% sodium bicarbonate.
After washing cells twice with 2% FCS medium, serial compound
dilutions (1:2) were added to each well (starting concentration
100 mg/mL), following by adding 100 mL of 2% of phosphate buffered
saline (PBS) culture medium containing 100 mL 50% cell cultureinfectious doses (i.e., CCID50) of virus. After 7 days of incubation, 2%
FCS culture medium was discarded and cells were ﬁxed with
ethanol and stained with 1% methylene blue, and EC50 and CC50
were determinate visually. The 50% effective concentration (EC50),
which is deﬁned as the compound concentration that is required to
inhibit the virus-induced cytopathogenic effect (CPE) by 50%, and
50% cytotoxic concentration (CC50), which is deﬁned as the com-
pound concentration that is required to inhibit the cell growth by
50%.
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